JP2015120706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015120706A5 JP2015120706A5 JP2015001336A JP2015001336A JP2015120706A5 JP 2015120706 A5 JP2015120706 A5 JP 2015120706A5 JP 2015001336 A JP2015001336 A JP 2015001336A JP 2015001336 A JP2015001336 A JP 2015001336A JP 2015120706 A5 JP2015120706 A5 JP 2015120706A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- antigen binding
- peptide
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 102000025171 antigen binding proteins Human genes 0.000 claims 23
- 108091000831 antigen binding proteins Proteins 0.000 claims 23
- 150000001413 amino acids Chemical group 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 5
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 5
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 4
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 3
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 3
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 2
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 2
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 2
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 2
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 2
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 claims 2
- 229940083963 Peptide antagonist Drugs 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 102000017916 BDKRB1 Human genes 0.000 claims 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 claims 1
- 108010044231 Bradykinin B1 Receptor Proteins 0.000 claims 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 108010056852 Myostatin Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 1
- 125000001151 peptidyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000010188 recombinant method Methods 0.000 claims 1
- 230000007704 transition Effects 0.000 description 3
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21059409P | 2009-03-20 | 2009-03-20 | |
| US61/210,594 | 2009-03-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012501019A Division JP2012521197A (ja) | 2009-03-20 | 2010-03-19 | 担体免疫グロブリンおよびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017077334A Division JP6345832B2 (ja) | 2009-03-20 | 2017-04-10 | 担体免疫グロブリンおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015120706A JP2015120706A (ja) | 2015-07-02 |
| JP2015120706A5 true JP2015120706A5 (cg-RX-API-DMAC7.html) | 2016-09-01 |
| JP6173359B2 JP6173359B2 (ja) | 2017-08-02 |
Family
ID=42740266
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012501019A Pending JP2012521197A (ja) | 2009-03-20 | 2010-03-19 | 担体免疫グロブリンおよびその使用 |
| JP2012501020A Pending JP2012521360A (ja) | 2009-03-20 | 2010-03-19 | Ｋｖ１．３の選択的かつ強力なペプチド阻害剤 |
| JP2015001336A Active JP6173359B2 (ja) | 2009-03-20 | 2015-01-07 | 担体免疫グロブリンおよびその使用 |
| JP2017077334A Active JP6345832B2 (ja) | 2009-03-20 | 2017-04-10 | 担体免疫グロブリンおよびその使用 |
| JP2018097620A Active JP6609347B2 (ja) | 2009-03-20 | 2018-05-22 | 担体免疫グロブリンおよびその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012501019A Pending JP2012521197A (ja) | 2009-03-20 | 2010-03-19 | 担体免疫グロブリンおよびその使用 |
| JP2012501020A Pending JP2012521360A (ja) | 2009-03-20 | 2010-03-19 | Ｋｖ１．３の選択的かつ強力なペプチド阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017077334A Active JP6345832B2 (ja) | 2009-03-20 | 2017-04-10 | 担体免疫グロブリンおよびその使用 |
| JP2018097620A Active JP6609347B2 (ja) | 2009-03-20 | 2018-05-22 | 担体免疫グロブリンおよびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US8734796B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3385279B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP2012521197A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2010226391C1 (cg-RX-API-DMAC7.html) |
| CA (4) | CA3018235C (cg-RX-API-DMAC7.html) |
| MX (4) | MX347291B (cg-RX-API-DMAC7.html) |
| WO (2) | WO2010108153A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| AU2008262490B2 (en) | 2007-05-22 | 2011-11-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| US20110189206A1 (en) | 2008-01-03 | 2011-08-04 | Barbas Iii Carlos F | Antibody Targeting Through a Modular Recognition Domain |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| CA3018235C (en) | 2009-03-20 | 2021-01-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| TW201129379A (en) | 2009-11-20 | 2011-09-01 | Amgen Inc | Anti-Orai1 antigen binding proteins and uses thereof |
| US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
| AU2011305306C1 (en) | 2010-09-22 | 2016-02-18 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| HK1198173A1 (en) | 2011-03-16 | 2015-03-13 | Amgen Inc. | Potent and selective inhibitors of nav1.3 and nav1.7 |
| CN102718858B (zh) * | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| KR20140038501A (ko) | 2011-06-06 | 2014-03-28 | 키네타 원, 엘엘씨 | Shk-기초된 제약학적 조성물 및 이들을 제조하고 이용하는 방법 |
| PL2718320T3 (pl) * | 2011-06-10 | 2018-06-29 | Medimmune Limited | Cząsteczki wiążące przeciwko PSL Pseudomonas i ich zastosowanie |
| SI2718318T1 (sl) | 2011-06-10 | 2018-11-30 | Hanmi Science Co., Ltd. | Novi derivati oksintomodulina in le-te obsegajoča farmacevtska sestava za zdravljenje debelosti |
| ES2710356T3 (es) | 2011-06-17 | 2019-04-24 | Hanmi Science Co Ltd | Conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo |
| KR102184343B1 (ko) | 2011-11-07 | 2020-11-30 | 메디뮨 엘엘씨 | 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법 |
| KR101895047B1 (ko) * | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
| BR112014030098A2 (pt) * | 2012-06-04 | 2017-07-25 | Irm Llc | métodos de rotulagem específica de sítio e moléculas produzidas pelos mesmos |
| US9283241B2 (en) * | 2012-07-10 | 2016-03-15 | Clemson University | Treatment to render implants resistant to diabetes |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| EP2906599B1 (en) | 2012-10-12 | 2019-07-17 | Agency For Science, Technology And Research | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| TWI652071B (zh) * | 2012-11-06 | 2019-03-01 | 韓美藥品股份有限公司 | 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑 |
| WO2014116937A1 (en) * | 2013-01-25 | 2014-07-31 | Janssen Biotech, Inc. | Kv1.3 antagonists and methods of use |
| AR096927A1 (es) | 2013-03-12 | 2016-02-10 | Amgen Inc | INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7 |
| TW201446792A (zh) | 2013-03-12 | 2014-12-16 | Amgen Inc | Nav1．7之強效及選擇性抑制劑 |
| EA201890895A1 (ru) | 2013-03-15 | 2019-02-28 | Зинджения, Инк. | Мультивалентные и моновалентные мультиспецифические комплексы и их применение |
| WO2015061826A1 (en) | 2013-10-28 | 2015-05-07 | Monash University | Novel scorpion toxin analogue and method for treating autoimmune diseases |
| CN106459981A (zh) * | 2013-12-23 | 2017-02-22 | 酵活有限公司 | 包含c端轻链多肽延伸的抗体和缀合物及其使用方法 |
| EP3152238A4 (en) * | 2014-06-06 | 2018-01-03 | The California Institute for Biomedical Research | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof |
| EP3674314B8 (en) | 2014-06-10 | 2023-07-12 | Amgen Inc. | Apelin polypeptides |
| US9710451B2 (en) * | 2014-06-30 | 2017-07-18 | International Business Machines Corporation | Natural-language processing based on DNA computing |
| WO2016023072A1 (en) * | 2014-08-15 | 2016-02-18 | Monash University | Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| WO2016054114A1 (en) | 2014-09-29 | 2016-04-07 | The Regents Of The University Of California | Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| US20180264080A1 (en) * | 2015-01-09 | 2018-09-20 | Kineta One, Llc | TOPICAL APPLICATIONS OF Kv1.3 CHANNEL BLOCKING PEPTIDES TO TREAT SKIN INFLAMMATION |
| US10787517B2 (en) | 2015-05-18 | 2020-09-29 | Agensys, Inc. | Antibodies that bind to AXL proteins |
| EP3297662A4 (en) | 2015-05-18 | 2019-03-13 | Agensys, Inc. | ANTIBODIES BINDING TO AXL PROTEINS |
| JP6924708B2 (ja) * | 2015-06-29 | 2021-08-25 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Ｂ１ｓｐ融合タンパク質の治療薬、方法、および使用 |
| HK1257840A1 (zh) | 2015-09-01 | 2019-11-01 | Agenus Inc. | 抗-pd-1抗体及其使用方法 |
| TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| US10388404B2 (en) | 2015-10-27 | 2019-08-20 | International Business Machines Corporation | Using machine-learning to perform linear regression on a DNA-computing platform |
| WO2017083604A1 (en) | 2015-11-12 | 2017-05-18 | Amgen Inc. | Triazine mediated pharmacokinetic enhancement of therapeutics |
| US11161891B2 (en) | 2015-12-09 | 2021-11-02 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
| KR20180104036A (ko) | 2016-01-22 | 2018-09-19 | 머크 샤프 앤드 돔 코포레이션 | 항-응고 인자 xi 항체 |
| US10865244B2 (en) | 2016-04-18 | 2020-12-15 | Celldex Therapeutics, Inc. | Nucleic acids encoding agonistic antibodies that bind CD40 |
| TWI802193B (zh) | 2016-06-14 | 2023-05-11 | 美商默沙東有限責任公司 | 抗凝血因子ｘｉ抗體 |
| WO2018013483A1 (en) * | 2016-07-11 | 2018-01-18 | The California Institute For Biomedical Research | Kv1.3 channel blocking peptides and uses thereof |
| AU2017373945B2 (en) | 2016-12-07 | 2025-01-23 | Agenus Inc. | Antibodies and methods of use thereof |
| JP7178701B2 (ja) * | 2017-01-19 | 2022-11-28 | 国立大学法人 東京大学 | 新規蛍光標識方法 |
| US11208477B2 (en) | 2019-04-01 | 2021-12-28 | Novo Nordisk A/S | Antibodies and use thereof |
| IL293450A (en) | 2019-12-03 | 2022-07-01 | Evotec Int Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| US11028132B1 (en) | 2020-04-07 | 2021-06-08 | Yitzhak Rosen | Half-life optimized linker composition |
| JP7458085B2 (ja) * | 2021-07-28 | 2024-03-29 | 株式会社三協 | 錠剤用崩壊剤及びこれを利用した錠剤 |
| WO2025122817A1 (en) * | 2023-12-06 | 2025-06-12 | The General Hospital Corporation | Antagonistic cd40 antibodies |
| WO2025122929A1 (en) * | 2023-12-08 | 2025-06-12 | Janssen Biotech, Inc. | Gprc5d antibodies with enhanced effector function and uses thereof |
| US20250276080A1 (en) | 2024-02-29 | 2025-09-04 | Amgen Inc. | Glucagon receptor agonists and conjugates to glucose-dependent insulinotropic polypeptide antagonists |
| WO2025209486A1 (en) | 2024-04-02 | 2025-10-09 | Keymed Biosciences (Chengdu) Co., Ltd. | Antibodies targeting il-13 and tslp and uses thereof |
| WO2025244108A1 (ja) * | 2024-05-23 | 2025-11-27 | 国立大学法人 東京大学 | 新規蛍光標識方法 |
| US12161970B1 (en) | 2024-08-09 | 2024-12-10 | Jiaxing Research Institute, Zhejiang University | CO2 desorption system suitable for limited space in complex sailing region and flexible control method |
Family Cites Families (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30985A (en) | 1860-12-18 | Thomas l | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| EP0315456B1 (en) | 1987-11-05 | 1994-06-01 | Hybritech Incorporated | Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| EP0387319B1 (en) | 1988-07-23 | 1996-03-06 | Delta Biotechnology Limited | Secretory leader sequences |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| FI92507C (fi) | 1991-12-19 | 1994-11-25 | Valto Ilomaeki | Menetelmä ja laite maaperään pakotettavien putkien ohjaamiseksi |
| JP3571337B2 (ja) | 1992-02-11 | 2004-09-29 | セル ジェネシス，インコーポレーテッド | 遺伝子標的現象による同型遺伝子接合 |
| WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| US6534051B1 (en) * | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
| EP0628078B1 (en) | 1992-12-11 | 1999-12-08 | The Dow Chemical Company | Multivalent single chain antibodies |
| US6342225B1 (en) | 1993-08-13 | 2002-01-29 | Deutshces Wollforschungsinstitut | Pharmaceutical active conjugates |
| EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
| AU1843295A (en) | 1994-02-23 | 1995-09-11 | Chiron Corporation | Method and compositions for increasing the serum half-life of pharmacologically active agents |
| US6054287A (en) | 1994-05-27 | 2000-04-25 | Methodist Hospital Of Indiana, Inc. | Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AU696775B2 (en) | 1995-03-23 | 1998-09-17 | Kirin-Amgen, Inc. | IL-17 receptor |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US5746516A (en) | 1995-08-11 | 1998-05-05 | Hitachi Powdered Metals Co., Ltd. | Porous bearing system having internal grooves and electric motor provided with the same |
| US5834431A (en) | 1995-09-08 | 1998-11-10 | Cortech, Inc. | Des-Arg9 -BK antagonists |
| US5849863A (en) | 1995-09-08 | 1998-12-15 | University Of Colorado | Cytolytic bradykinin antagonists |
| WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| GB9712818D0 (en) | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| US6077680A (en) * | 1996-11-27 | 2000-06-20 | The University Of Florida | ShK toxin compositions and methods of use |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| ES2247642T3 (es) | 1996-12-26 | 2006-03-01 | Suntory Limited | Neuropeptidos procedentes del escorpion. |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US20030044772A1 (en) | 1997-08-04 | 2003-03-06 | Applied Molecular Evolution [Formerly Ixsys] | Methods for identifying ligand specific binding molecules |
| US6022952A (en) | 1998-04-01 | 2000-02-08 | University Of Alberta | Compositions and methods for protein secretion |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| ME00238B (me) | 1998-10-23 | 2011-02-10 | Kirin Amgen Inc | Mimičko vezivanje dimernog trombopoitetinskog peptida za mp1 receptor sa trombopoietičkom aktivnošću |
| AU765111B2 (en) | 1998-11-20 | 2003-09-11 | Fuso Pharmaceutical Industries, Ltd. | Protein expression vector and utilization thereof |
| CA2368068A1 (en) | 1999-03-18 | 2000-09-21 | Steven M. Ruben | 27 human secreted proteins |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| FR2794461B1 (fr) | 1999-06-07 | 2004-01-23 | Lab Francais Du Fractionnement | Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
| PL357448A1 (en) | 2000-02-25 | 2004-07-26 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof |
| EP1803730A1 (en) | 2000-04-12 | 2007-07-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| US20050054051A1 (en) | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| MXPA03010210A (es) | 2001-05-11 | 2004-03-10 | Amgen Inc | Peptidos y moleculas relacionadas que se enlazan a tall-1. |
| DE60235013D1 (de) | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| WO2003025020A1 (en) | 2001-09-13 | 2003-03-27 | Institute For Antibodies Co., Ltd. | Method of constructing camel antibody library |
| US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
| EP1467756A4 (en) | 2001-12-28 | 2007-03-21 | Abgenix Inc | METHODS OF USING ANTI-MUC18 ANTIBODIES |
| WO2003080672A1 (en) | 2002-03-22 | 2003-10-02 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| EP2382990B1 (en) | 2003-04-30 | 2014-09-17 | Universität Zürich | Methods for treating cancer using an immunotoxin |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| DE602004032370D1 (de) * | 2003-10-16 | 2011-06-01 | Imclone Llc | Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür |
| US7605120B2 (en) | 2003-10-22 | 2009-10-20 | Amgen Inc. | Antagonists of the brandykinin B1 receptor |
| EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| PL2177537T3 (pl) * | 2004-01-09 | 2012-06-29 | Pfizer | Przeciwciała przeciw MadCAM |
| GB0414272D0 (en) | 2004-06-25 | 2004-07-28 | Cellpep Sa | OsK1 derivatives |
| WO2006036834A2 (en) | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
| ES2580233T3 (es) * | 2004-10-07 | 2016-08-22 | The Regents Of The University Of California | Análogos de toxina ShK y sus usos en inhibición selectiva de canales de potasio Kv1.3 |
| CA2587463A1 (en) | 2004-11-16 | 2006-11-30 | Avidia Research Institute | Protein scaffolds and uses therof |
| JP2008520207A (ja) | 2004-11-16 | 2008-06-19 | アヴィディア リサーチ インスティテュート | タンパク質骨格およびその使用 |
| AU2005307831A1 (en) * | 2004-11-17 | 2006-05-26 | Amgen, Inc. | Fully human monoclonal antibodies to IL-13 |
| WO2006068953A2 (en) | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| AR054165A1 (es) | 2005-07-13 | 2007-06-06 | Avidia Inc | Proteinas de union a il-6 |
| US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| TW200722436A (en) | 2005-10-21 | 2007-06-16 | Hoffmann La Roche | A peptide-immunoglobulin-conjugate |
| US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| AU2007343796A1 (en) | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
| EP3029461B1 (en) * | 2006-11-01 | 2017-12-20 | Ventana Medical Systems, Inc. | Haptens, hapten conjugates, compositions thereof and method for their preparation and use |
| US8280711B2 (en) | 2007-03-12 | 2012-10-02 | ESBATech, an Alcon Biomedical Research Unit, LLC. | Sequence based engineering and optimization of single chain antibodies |
| US8793074B2 (en) | 2007-06-21 | 2014-07-29 | Saint Louis University | Sequence covariance networks, methods and uses therefor |
| KR101573086B1 (ko) | 2007-06-25 | 2015-11-30 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 항체를 변형시키는 방법, 및 기능적 특성이 개선된 변형된 항체 |
| CA2694488A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| WO2009086411A2 (en) | 2007-12-27 | 2009-07-09 | Abbott Laboratories | Negative mimic antibody for use as a blocking reagent in bnp immunoassays |
| WO2009115609A1 (en) | 2008-03-20 | 2009-09-24 | Csl Behring Gmbh | The calcium sensor STIM1 and the platelet SOC channel Orai1 (CRACM1) are essential for pathological thrombus formation |
| CA2742968C (en) * | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| WO2010088522A2 (en) | 2009-01-30 | 2010-08-05 | Ab Biosciences, Inc. | Novel lowered affinity antibodies and uses therefor |
| CA3018235C (en) | 2009-03-20 | 2021-01-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| WO2011094593A2 (en) | 2010-01-28 | 2011-08-04 | Ab Biosciences, Inc. | Novel lowered affinity antibodies and methods of marking the same |
| AU2011305306C1 (en) | 2010-09-22 | 2016-02-18 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
-
2010
- 2010-03-19 CA CA3018235A patent/CA3018235C/en active Active
- 2010-03-19 CA CA2755336A patent/CA2755336C/en active Active
- 2010-03-19 WO PCT/US2010/028060 patent/WO2010108153A2/en not_active Ceased
- 2010-03-19 EP EP18173194.4A patent/EP3385279B1/en active Active
- 2010-03-19 US US13/258,668 patent/US8734796B2/en active Active
- 2010-03-19 JP JP2012501019A patent/JP2012521197A/ja active Pending
- 2010-03-19 EP EP10754210.2A patent/EP2408814B1/en active Active
- 2010-03-19 AU AU2010226391A patent/AU2010226391C1/en active Active
- 2010-03-19 WO PCT/US2010/028061 patent/WO2010108154A2/en not_active Ceased
- 2010-03-19 US US13/258,454 patent/US20120121591A1/en not_active Abandoned
- 2010-03-19 MX MX2014010300A patent/MX347291B/es unknown
- 2010-03-19 MX MX2011009798A patent/MX2011009798A/es active IP Right Grant
- 2010-03-19 EP EP10754211.0A patent/EP2432488A4/en not_active Withdrawn
- 2010-03-19 MX MX2011009797A patent/MX2011009797A/es not_active Application Discontinuation
- 2010-03-19 JP JP2012501020A patent/JP2012521360A/ja active Pending
- 2010-03-19 MX MX2014010302A patent/MX347295B/es unknown
- 2010-03-19 AU AU2010226392A patent/AU2010226392B9/en not_active Ceased
- 2010-03-19 CA CA2889453A patent/CA2889453C/en active Active
- 2010-03-19 CA CA2755133A patent/CA2755133A1/en not_active Abandoned
-
2014
- 2014-05-22 US US14/285,579 patent/US9562108B2/en active Active
- 2014-05-22 US US14/285,576 patent/US9562107B2/en active Active
-
2015
- 2015-01-07 JP JP2015001336A patent/JP6173359B2/ja active Active
-
2017
- 2017-01-12 US US15/405,233 patent/US10189912B2/en active Active
- 2017-04-10 JP JP2017077334A patent/JP6345832B2/ja active Active
-
2018
- 2018-05-22 JP JP2018097620A patent/JP6609347B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015120706A5 (cg-RX-API-DMAC7.html) | ||
| ES2991459T3 (es) | Ligantes de albúmina sérica mejorados | |
| ES2994387T3 (en) | Improved serum albumin binders | |
| JP2023027258A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP2019504032A5 (cg-RX-API-DMAC7.html) | ||
| JP2020506900A5 (cg-RX-API-DMAC7.html) | ||
| AU2012328917B2 (en) | Bispecific immunobinders directed against TNF and IL-17 | |
| JP2020524661A5 (cg-RX-API-DMAC7.html) | ||
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2015522252A5 (cg-RX-API-DMAC7.html) | ||
| AU2020201323A1 (en) | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof | |
| US20130171059A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| AU2014227664A1 (en) | Dual specific binding proteins directed against TNFalpha | |
| FI3569620T3 (fi) | Ihmisen cgrp-reseptoria sitovat vasta-aineet | |
| RU2016108703A (ru) | Антитело, специфически связывающееся с glp-1r, и его слитый с glp-1 белок | |
| JP2020536109A5 (cg-RX-API-DMAC7.html) | ||
| CN105992772A (zh) | IgA多特异性结合分子 | |
| JP2018535650A5 (cg-RX-API-DMAC7.html) | ||
| HRP20160494T1 (hr) | Antigen-vezujući proteini za proproteinsku konvertazu subtilizin keksin tipa 9 (pcsk9) | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| US20170015742A1 (en) | Binding proteins against vegf, pdgf, and/or their receptors | |
| WO2014144280A2 (en) | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17 | |
| RU2016129724A (ru) | Антитела, содержащие с-концевые удлинения полипептида легкой цепи, их конъюгаты и способы применения | |
| JP2020524658A5 (cg-RX-API-DMAC7.html) |